Table 2.
ESR1 agonist affects genes involved in crucial HCC pathways.
| Agonist vs Control (Female) Upregulated genes (n=266) | |
|---|---|
| Pathway Name | q-value (FDR: BH-method) |
| Nucleosome assembly (linked to histone) | 3.27E-24 |
| Mismatch repair | 5.25E-11 |
| Regulation of TP53 Activity through Methylation | 3.57E-02 |
| PRC2 methylates histones and DNA | 1.19E-06 |
| Agonist vs Control (Female) Downregulated genes (n=280) | |
| Wnt-β-catenin | 1.53E-07 |
| DNA replication initiation | 2.09E-04 |
| Hippo signaling | 1.58E-02 |
| PI3K_AKT_MTOR | 3.44E-02 |
| Wnt/Beta-catenin | 1.53E-07 |
| DNA replication initiation | 2.09E-04 |
| Hippo signaling | 1.58E-02 |
| Agonist vs Control (Male) Upregulated genes (n=173) | |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | 2.53E-02 |
| Agonist vs Control (Male) Downregulated genes (n=64) | |
| JNK MAPK Pathway | 4.25E-02 |
| Wnt Signaling | 2.53E-02 |
ESR1 agonist upregulates genes involved in Methylation and DNA mismatch repair and downregulates genes involved in cancer progression pathways, such as Wnt-β-catenin signaling, PI3K-mTOR, DNA replication and Hippo pathway. FDR, False discovery Rate; BH, Benjamini-Hochberg.